USPTO Examiner ROSENTHAL ANDREW S - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18725983DETERMINATION OF THE TRAPPED VOLUME OF A LIPOSOMEJuly 2024February 2026Allow2000NoNo
18751134PHENYLEPHRINE HYDROCHLORIDE COMPOSITIONS AND CONTAINERSJune 2024July 2025Allow1331YesNo
18674999LYCOPENE COMPOSITIONS AND METHODS FOR PROTECTING SKIN AGAINST ULTRAVIOLET RADIATIONMay 2024July 2025Allow1420NoNo
18637772INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAMEApril 2024August 2025Abandon1610NoNo
18629406METHOD AND KIT FOR BOWEL PREPARATIONApril 2024April 2025Allow1210YesNo
18612888CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLESMarch 2024May 2025Allow1400YesNo
18693714URIC ACID LIPOSOMESMarch 2024December 2025Allow2100YesNo
18587736EMBOLIC COMPOSITIONSFebruary 2024April 2025Allow1310YesNo
18582320PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATEFebruary 2024June 2025Allow1611NoNo
18414007PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORESJanuary 2024February 2026Abandon2540YesNo
18529962NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUSDecember 2023August 2024Allow800YesNo
18493428NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDSOctober 2023November 2025Allow2511NoNo
18491529COMPOSITIONS COMPRISING PGI2-RECEPTOR AGONISTS AND PROCESSES FOR THE PREPARATION THEREOFOctober 2023January 2026Allow2720YesNo
18376545METHOD FOR TREATING LIVER CIRRHOSIS BY USING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOROctober 2023January 2026Allow2710NoNo
18480331MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITYOctober 2023October 2024Abandon1310NoNo
18244391INTRANASAL DELIVERY OF CANNABIDIOL TO TREAT CENTRAL NERVOUS SYSTEM DISORDERSSeptember 2023November 2024Abandon1420NoYes
18455930METHOD FOR BOWEL PREPARATIONAugust 2023October 2024Allow1320NoNo
18547801LOW PH CO-EXTRACTION METHOD OF PREPARING A STABLE OIL BODY SOLUTIONAugust 2023March 2026Allow3101YesNo
18277896Odorous Compounds and Method of Preparation ThereofAugust 2023October 2025Allow2610YesNo
18546134METHODS OF LOADING EXTRACELLULAR VESICLESAugust 2023January 2026Allow3010NoNo
18358795SYSTEMS AND METHODS FOR PREPARING AND TRANSPORTING AN INJECTABLE SLURRYJuly 2023March 2026Abandon3230NoNo
18225475FORMULATIONS COMPRISING CYCLOSPORIN AJuly 2023October 2024Abandon1510NoNo
18223252THERAPEUTIC CLAY COMPOSITIONS AND METHODS OF USINGJuly 2023July 2024Allow1210NoNo
18271621COSMETIC SALTSJuly 2023February 2026Allow3100YesNo
18012295PLATINUM-BASED DRUG-/PHOTOSENSITIZER-LOADED PROTEIN NANOPARTICLE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFJuly 2023January 2026Allow3710NoNo
18345643COMPOSITIONS AND METHODS RELATED TO RHAMNUS PRINOIDES (GESHO) EXTRACT FOR THE INHIBITION OF POLYMICROBIAL BIOFILM FORMATIONJune 2023April 2025Allow2220YesNo
18332487LIPID NANOPARTICLE FORMULATIONSJune 2023December 2024Allow1811NoNo
18306402PERSONAL CARE PRODUCTS COMPRISING HIGHLY CATIONIC SUBSTITUTED STARCHESApril 2023May 2025Abandon2420NoNo
18188780DOSING WITH AN AZOLOPYRIMIDINE COMPOUNDMarch 2023May 2024Abandon1410NoNo
18187132ANTIMICROBIAL TOPICAL COMPOSITIONS CONTAINING MANUKA OILMarch 2023October 2024Abandon1901NoNo
18185175TRANSDERMAL PATCHMarch 2023April 2024Abandon1301NoNo
18115890Methods of Making CapsulesMarch 2023June 2025Allow2800YesNo
18172242METHODS OF ADMINISTERING GLUTATHIONE PRECURSORSFebruary 2023February 2026Allow3531NoNo
18167123FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENTFebruary 2023March 2024Allow1310YesNo
18019632ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIESFebruary 2023July 2025Allow2900YesNo
18100363NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUSJanuary 2023September 2023Allow700YesNo
18099829DRY POWDER INHALATION SYSTEMJanuary 2023November 2025Allow3410YesNo
18003791WATER-SOLUBLE FILM AND PACKAGEDecember 2022March 2026Allow3810NoNo
18089861PAINTING WITH BIOCIDES COMPOSITION AND/OR PROLONGED RELEASE PESTICIDESDecember 2022May 2025Abandon2910NoNo
18067164USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODORDecember 2022December 2025Abandon3611NoNo
18078469ELECTROCHEMICAL ATTACHMENT OF PHOSPHONIC ACIDS TO METALLIC SUBSTRATES AND ANTIMICROBIAL MEDICAL DEVICES CONTAINING SAMEDecember 2022July 2025Abandon3131NoNo
18000832POLYURETHANES BASED ON TERMINAL DIOL- AND DIAMINOPOLYPHOSPHAZENES AND THEIR HYDROGELSDecember 2022December 2025Abandon3610YesNo
18007705KINASE INHIBITORSDecember 2022June 2025Allow3000YesNo
18056771INJECTABLE AND INHALABLE FORMULATIONSNovember 2022April 2025Allow2940YesNo
17988890PHOTOSTABILIZING COMPOUNDS, COMPOSITIONS, AND METHODSNovember 2022July 2023Allow800YesNo
17998568Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide UreasNovember 2022December 2025Allow3720NoNo
17966668INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAMEOctober 2022September 2023Allow1100NoNo
17917820MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVESOctober 2022October 2025Abandon3610YesNo
17915952Method for Treating SARS and Treating or Preventing ARDSSeptember 2022May 2025Allow3200YesNo
17912845CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOFSeptember 2022November 2025Abandon3810YesNo
17896808LEVODOPA FRACTIONATED DOSE COMPOSITION AND USEAugust 2022August 2023Allow1200YesNo
17893716MANUFACTURING METHOD OF HEMOSTATIC MATERIAL AND HEMOSTATIC MATERIAL PREPARED THEREBYAugust 2022February 2025Abandon2920NoNo
17878652ANTIMICROBIAL COMPOSITIONS AND METHODSAugust 2022January 2026Allow4120YesNo
17870313LIPID COMPOUND AS WELL AS LIPID CARRIER, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING SAMEJuly 2022March 2023Allow811NoNo
17792946CROSSLINKED DEXTRAN-BASED HYDROGELS AND USES THEREOFJuly 2022December 2025Abandon4101NoNo
17864332COMPOSITION AS AUXILIARY MEANS FOR ORAL MEDICATIONJuly 2022March 2024Allow2110NoNo
17849887METHOD AND KIT FOR BOWEL PREPARATIONJune 2022January 2024Allow1820NoNo
17808649HETEROCYCLIC COMPOUNDS AND NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING SAMEJune 2022November 2023Abandon1720NoNo
17848351TREATMENT SYSTEM FOR POST MARINE ENVENOMATIONJune 2022October 2025Allow4010YesNo
17784555PHOSPHATE-CONTAINING ANTI-CORROSIVE PIGMENTJune 2022June 2025Allow3600NoNo
17832997SYSTEM AND METHOD FOR THERAPEUTIC COMPOSITIONS FROM A PLURALITY OF DIFFERENT BIRTH TISSUES AND EXOSOMESJune 2022October 2024Allow2911YesNo
17782425PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG BIS(MONOETHANOLAMINE)June 2022May 2025Allow3510NoNo
17781879Scaffold Using Adipose Tissue-Derived Extracellular Matrix and Method for Producing SameJune 2022November 2025Abandon4210NoNo
17824654METHOD OF TREATMENTMay 2022March 2024Allow2210YesNo
17750970PHOTOCHEMICALLY STABLE, NON-LEACHING, BRIDGED POLYSILSESQUIOXANE BASED SUNSCREENSMay 2022March 2025Allow3400YesNo
17777721HAIR CARE COMPOSITIONMay 2022September 2025Allow4020YesNo
17744534SYSTEMS AND METHODS FOR PREPARING AND TRANSPORTING AN INJECTABLE SLURRYMay 2022July 2023Abandon1410NoNo
17720572COMPOSITIONS AND METHODS FOR USING ANDROGEN SIGNALING INHIBITORSApril 2022February 2025Abandon3411NoNo
17658288Personal Care Compositions for Treating Odor Causing Bacteria and Methods for the SameApril 2022September 2024Allow3041YesNo
17657370PLASTER FOR USE IN THE CONTEXT OF AN INTRAMUSCULAR INJECTION, IN PARTICULAR A VACCINATIONMarch 2022July 2025Allow4020NoNo
17653575PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORESMarch 2022March 2024Abandon2410NoNo
17753307Composition and Method for treatment of diabetesFebruary 2022February 2025Allow3600NoNo
17637794Method to Incorporate Oleanolic Acid into Oral Care Compositions and Oral Care Compositions Based ThereofFebruary 2022September 2025Allow4321YesNo
17621778Oral Care Compositions Comprising Star-Shaped PolymersDecember 2021November 2024Allow3500NoNo
17621312HIGH THROUGHPUT MANUFACTURE OF POLYURETHANE FOAM LAYERSDecember 2021August 2025Allow4410YesNo
17551550Pharmaceutical Compositions of Dimethyl FumarateDecember 2021January 2024Allow2511NoNo
17616074A POLYMER AND A TOPICAL COMPOSITION COMPRISING THE POLYMERDecember 2021August 2024Allow3300NoNo
17535080CARBON MONOXIDE-BASED THERAPIES AND IMPLANTABLE DEVICES FOR THE TREATMENT OF VASCULAR DISEASENovember 2021March 2024Allow2711YesNo
17535493INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAMENovember 2021May 2022Allow610YesNo
17612468TREATMENT OF SYSTOLIC DYSFUNCTIONNovember 2021January 2025Abandon3710NoNo
17610175BIOACTIVE GLASS COMPOSITIONSNovember 2021June 2025Allow4320YesNo
17606701MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOFOctober 2021November 2025Allow4920YesNo
17601404INCREASING THE STABILITY OF AGENTS FOR THE TREATMENT OF KERATINOUS MATERIALOctober 2021November 2025Allow4920NoNo
17599253POLYMER AGENTS FOR CARDIOPULMONARY RESUSCITATIONSeptember 2021March 2025Allow4110YesNo
17598160IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOFSeptember 2021December 2024Allow3910NoNo
17469232METHOD FOR LIQUID-TO-SOLID PHASE SEPARATION OF URANIUM AND URANYL CONTAMINANT FROM VARIOUS SOLUTIONSSeptember 2021March 2025Abandon4221NoNo
17468349Polycationic Amphiphiles as Antimicrobial Agents and Methods Using SameSeptember 2021July 2025Allow4631YesNo
17464256SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTYSeptember 2021June 2023Abandon2210NoNo
17464268SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTYSeptember 2021January 2024Abandon2820NoNo
17435110INDUCING CASPASE ACTIVITYAugust 2021November 2024Allow3920NoNo
17400957COMPOSITIONS COMPRISING PGI2-RECEPTOR AGONISTS AND PROCESSES FOR THE PREPARATION THEREOFAugust 2021July 2023Allow2310NoNo
17443743FRAGRANCE COMPOSITIONJuly 2021April 2025Abandon4541YesNo
17384629COMPOSITION AND METHOD FOR REDUCING THE INFECTIVITY AND VIRUCIDAL ACTIVITY OF SARS-COV-2July 2021August 2023Abandon2510NoNo
17378083CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLESJuly 2021December 2023Allow2911YesNo
17376237COMPOSITION FOR A FORMULATED ORAL PREBIOTIC EDIBLE COMPOSITIONJuly 2021September 2023Allow2710YesNo
17423377METHOD FOR ORAL CAVITY CAREJuly 2021March 2025Abandon4420NoNo
17371715BIODEGRADABLE PIEZOELECTRIC COMPOSITE MATERIALSJuly 2021August 2025Allow4911YesNo
17366620EMBOLIC COMPOSITIONSJuly 2021October 2023Allow2810NoNo
17418940ADAMANTANECARBOXYLIC ACID BENZYL AMIDE DERIVATIVE COMPOUND AND SKIN WHITENING COMPOSITION COMPRISING SAMEJune 2021May 2024Allow3420YesNo
17356131KITS FOR TREATING THE HAIRJune 2021July 2023Abandon2510NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROSENTHAL, ANDREW S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
34
Examiner Affirmed
25
(73.5%)
Examiner Reversed
9
(26.5%)
Reversal Percentile
42.4%
Lower than average

What This Means

With a 26.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
111
Allowed After Appeal Filing
17
(15.3%)
Not Allowed After Appeal Filing
94
(84.7%)
Filing Benefit Percentile
18.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ROSENTHAL, ANDREW S - Prosecution Strategy Guide

Executive Summary

Examiner ROSENTHAL, ANDREW S works in Art Unit 1613 and has examined 658 patent applications in our dataset. With an allowance rate of 53.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner ROSENTHAL, ANDREW S's allowance rate of 53.3% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ROSENTHAL, ANDREW S receive 2.52 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROSENTHAL, ANDREW S is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +45.2% benefit to allowance rate for applications examined by ROSENTHAL, ANDREW S. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.2% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.6% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 56.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 48.5% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 56.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.